Chemistry:Vipadenant
From HandWiki
Vipadenant (INN, USAN; developmental code name BIIB014 and others) is an adenosine A2A receptor antagonist which was under development for the treatment of Parkinson's disease and cancer but was never marketed.[1][2][3][4] It is taken orally.[1] The drug was first described in the scientific literature by 2006.[5][6] It was under development by Vernalis, Biogen, and Juno Therapeutics.[1][2] Vipadenant reached phase 2 clinical trials prior to the discontinuation of its development.[1][2]
See also
- Adenosine receptor antagonist
- List of investigational Parkinson's disease drugs
References
- ↑ 1.0 1.1 1.2 1.3 "Vipadenant". 28 October 2024. https://adisinsight.springer.com/drugs/800016777.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on Vipadenant with Synapse". 24 January 2026. https://synapse.patsnap.com/drug/c345f903f0424159a27dbca940ff07b2.
- ↑ "Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued". CNS Drugs 28 (5): 455–474. May 2014. doi:10.1007/s40263-014-0161-7. PMID 24687255.
- ↑ "An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers". Clinical Neuropharmacology 33 (2): 55–60. 2010. doi:10.1097/WNF.0b013e3181d137d2. PMID 20375654.
- ↑ Lightowler, S., Knight, A. R., & Upton, R. (2006). Pharmacology of BIIB014/V2006, an A2A antagonist for the treatment of PD. Targeting Adenosine A2A Receptors in Parkinson’s Disease and Other CNS Disorders. Boston, USA. https://scholar.google.com/scholar?cluster=5861921750099200903
- ↑ "Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines". Journal of Medicinal Chemistry 52 (1): 33–47. January 2009. doi:10.1021/jm800961g. PMID 19072055.
 |  |
